thermo scientific



Thermo Scientific reagents for immunosuppressant drug testing

Complete solutions for patient monitoring



Thermo Scientific™ QMS™ **Everolimus Immunoassay**

Accurate: Correlates well with gold standard method LC-MS/MS Efficient: Excellent accuracy across assay range Rapid: Quick turn-around-time Limit Of Quantitation (LOQ): 2 ng/mL Reportable Range: 2 to 20 ng/mL

Reference Method Comparison

Hitachi™ Analyzer vs. LC-MS/MS

Sample Type	NI	Passing Bablok Regression		Operation Operations (v)	
	N	Slope	Intercept	correlation coefficient (r)	
Kidney	150	1.11	-0.01	0.96	
Liver	111	0.98	-0.06	0.93	
Heart*	41	1.00	-0.15	0.96	
* Heart indication is ex-	US only				

A correlation study was performed using 178 samples from adult liver transplant recipients. Results from the QMS Everolimus assay were compared with results from LC-MS/MS methods; both methods were used in the everolimus drug trial for liver transplantation.

Summary Method Comparison Regression Analysis with Liver Transplant Patient Samples

Method	Ν	Slope 95% Cl		tercept 15% Cl	R
LC-MS/MS System 3	170	1.02		0.15	0.07
vs. QMS	178 —	(0.99 to 1.06)	(-0.11 to 0.40)		- 0.97
		Avg Bias (ng	g/mL)	Bias SD	Avg. % Bias
LC-MS/MS System 3 vs. QMS		0.29		0.76	4.00



Deming Regression Analysis: Slope was 1.02, and intercept was 0.15 with a correlation coefficient of 0.97.

vs. LC-MS/MS method.



EVEROLIMUS IMMUNOASSAY

Item Number	Description	Format
10015987	QMS Everolimus Immunoassay	R1 22 mL, R2 8 mL
380005	QMS Everolimus Calibrator Set	6 levels, 3 mL 1 vial each
380010	QMS Everolimus Control Set	3 levels 3 mL 1 vial each

Ordering: for use in the European Union

Item Number	Description	Format
10015993	QMS Everolimus Immunoassay*	R1 22 mL, R2 8 mL
373860	QMS Everolimus Calibrator Set*	6 levels, 3 mL 1 vial each
373878	QMS Everolimus Control Set*	3 levels 3 mL 1 vial each

* not available in US

Thermo Scientific QMS Tacrolimus Immunoassay

Accurate: Correlates well with the gold standard LC-MS/MS methods Efficient: Quick turn-around of patient results Convenient: liquid, ready-to-use reagents Limit of Quantitation: (LOQ): 0.9 ng/mL

Reportable Range: 1.0 - 30.0 ng/mL

Precision

Precision was evaluated using whole blood pooled patient and spiked samples. The study was conducted as described in CLSI protocol EP5-A3.¹ Each sample was assayed in duplicates per run, twice a day for 20 days. The mean, the within-run and total-run SD and %CV were calculated. Representative results are shown below.

			With	in-Run	Tota	I-Run
Sample	Ν	Mean (ng/mL)	SD	% CV	SD	% CV
Spiked Sample A	80	3.0	0.2	4.9	0.2	7.1
Spiked Sample B	80	10.0	0.2	1.9	0.4	3.6
Spiked Sample C	80	20.9	0.4	1.9	1.1	5.0
Patient Sample A	80	3.2	0.1	4.1	0.2	6.2
Patient Sample B	80	10.4	0.2	2.2	0.4	3.6
Patient Sample C	80	24.2	0.5	2.1	1.1	4.6

Reference Method Comparison

Correlation studies were performed to compare the QMS Tacrolimus Immunoassay on the Beckman Coulter™ AU680 analyzer to the LC-MS/MS method. The results of the Deming regression analysis using the different transplant type samples are shown in the table below.

Transplant Type	Number	Slope	Intercept	Correlation
Kidney	136	1.077	0.98	0.980
Liver	133	1.127	0.21	0.963
Heart	114	1.108	0.36	0.974

Deming regression analysis result with all transplant patient samples are shown in the table below.

Comparative Method	Ν	Slope (95% CI*)	Intercept (95% CI)	Correlation Coefficient (R)	
LC MC/MC System 1	202	1.11	0.53	0.070	
LC-IVIS/IVIS System 1	303	(1.08 to 1.14)	(0.31 to 0.76)	0.972	

*Confidence Interval (CI)

1.) CLSI. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition. CLSI document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014

edures; Approved Guideline – Third Edition. ndards Institute; 2014 QMS Tacrolimus Calibrator Set 10015573 Level A Level B-F 280-1 Rap/Tac/CsA Control Level 1 280-2 Rap/Tac/CsA Control Level 2 280-3 Rap/Tac/CsA Control Level 3

QMS* Tacrolimus /

CE

TACROLIMUS

QMS® TACROLIMUS

Ordering: Item Number

10015556

Description

QMS Tacrolimus Immunoassay

Format

6 levels

4 mL, 1 vial

4 mL, 4 vials

4 mL, 4 vials

4 mL, 4 vials

2 mL, 1 vial each

R1 18 mL, R2 12 mL,

Extraction Reagent 50 mL

₩

CALIBRATOR SET

IVD

OMS

1 ACE

Method Comparison

Correlation studies were performed to compare the QMS Tacrolimus Immunoassay to LC-MS/MS System 1. The studies used 383 human whole blood EDTA specimens obtained from kidney, liver and heart transplant patients taking tacrolimus. All tested specimens were trough samples from mainly adult patients with time of post-transplant for the samples generally > 9 months. The patients tested received drug regimens of tacrolimus either alone or coadministered with other immunosuppressive drugs, mainly mycophenolate mofetil (MMF), mycophenolic acid (MPA), or corticosteroids. The results of the Deming regression analysis² between the two methods are shown in the table below.





Thermo Scientific™ CEDIA™ **Cyclosporine PLUS Assay**

Accurate: Lot-to-lot consistency Efficient: Two-point calibration curve **Convenient:** High and low range assays use same reagents Rapid: Single-lysing step for sample preparation Limit of Quantitation (LOQ): Limit of Quantitation is 25 ng/mL Reportable Range: 25 to 2000 ng/mL

Method Comparison - Low Range Assay

Comparisons using Microgenics CEDIA Cyclosporine PLUS (y) to HPLC-MS (x) at four sites provided following correlation on all transplant types.



Reference Method Comparison

Comparisons using Microgenics CEDIA Cyclosporine PLUS (y) to FPIA (x), EMIT® (x), and HPLC-MS (x) at four sites provided the following correlations. Refer to package insert for additional information on method comparison.

Transplant		Linear Regression Deming				D
Туре	X-AXIS	S _{yx}	S _{yx}	K	n	Kange
A 11		0.97x + 8	1.04x - 1	0.02	011	
All	HLC-IN2	26	18	0.93	311	20 – 366 Hy/HL
A 11		1.05x + 6	1.09x + 2	0.07	000	00 (10 mm/mm)
All	EIVIII	16	11	0.97	298	33 — 412 Ng/ML
A 11	A	1.00x + 2	1.05x - 5	0.05	000	
All Axsym	Axsym	19	13	0.95	290	35 – 368 Ng/ML
	TDv	0.87x - 18	0.91x - 25	0.05	000	0 000 ng/ml
All	TDX	20	15	0.95	298	9 – 386 ng/mL
= = =+ / = =:		0.87x + 32	0.93x + 23	0.04	100	01 000
Heart/Lung	HPLC-INS	26	19	0.94	109	31 — 383 ng/mL
1.5		1.07x - 0	1.18x - 9	0.01	0.0	41 000 /
Liver	HPLC-IVIS	21	13	0.91	80	41 — 386 ng/mL
		1.02x - 9	1.09x - 17	0.04	122	00 070 / 1
Kidney	HPLC-MS	24	16	- 0.94		26 – 379 ng/mL



Ordering:		
Item Number	Description	Format
10016283	CEDIA Cyclosporine PLUS Assay includes Low Range Calibrators A & B	R1 41mL, R2 19 mL, lysing reagent 98 mL, Cal A & B - 2 mL, 1 vial each
100012	CEDIA Cyclosporine PLUS High Range Calibrator Kit	2 levels, 4 mL 2 vials each
280-1	Rap/Tac/CsA Control Level 1	4 mL, 4 vials
280-2	Rap/Tac/CsA Control Level 2	4 mL, 4 vials
280-3	Rap/Tac/CsA Control Level 3	4 mL, 4 vials

CYCLOSPORINE PLUS ASSAY

Precision

Measured precision studies using packaged reagents, pooled whole blood, and whole blood controls yielded the following results in ng/mL on the Hitachi 911 analyzer. The study was conducted using CLSI modified replication experiment (3 replicates, daily for 21 days).

Low Range Assay						
		Mean	Within Run		Total	
	п		SD	CV%	SD	CV%
Control Level 1	63	46.2	3.7	8.0	7.4	16.0
Control Level 2	63	199.7	5.9	2.9	9.1	4.6
Control Level 3	63	418	31.7	7.6	40.5	9.6
Low Pool	63	54	4.7	8.8	6.6	12.2
High Pool	63	434.7	6.7	1.6	19.4	4.5

High Range Assay						
		Meen	Withi	n Run	То	otal
	п	n mean	SD	CV%	SD	CV%
Control Level 4	63	642	38.0	5.9	47.0	7.3
Control Level 5	63	1257	49.9	4.0	63.9	5.1
Low Pool	63	472	22.8	4.8	35.1	7.5
High Pool	63	1695	39.2	2.3	87.3	5.2







All Mycophen M 10277 51 au Calibrator D C C rc²

Method Comparison

A total of 188 pre-dose samples from adult transplant patients receiving mycophenolate mofetil or mycophenolate sodium therapy were tested in a method comparison study using LC-MS/MS as the reference method. The table below summarizes the results of the study with separate analysis by transplant type and combined results.

Sample	Ν	Regressi	R	
		Least Square slope	1.11 (1.06 to 1.17)	
	06	Least Square intercept	0.20 (0.05 to 0.36)	0.07
Plasifia Heart	90	Deming slope	1.15 (1.09 to 1.20)	0.97
		Deming intercept	0.12 (-0.04 to 0.28)	
		Least Square slope	1.13 (0.97 to 1.08)	
Dlaama Kidnay	00	Least Square intercept	0.16 (-0.03 to 0.36)	0.07
Plasifia Kluffey	92	Deming slope	1.06 (1.01 to 1.11)	0.97
		Deming intercept	0.06 (-0.13 to 0.25)	
		Least Square slope	1.05 (1.02 to 1.09)	
Plasma All	100	Least Square intercept	0.22 (0.09 to 0.34)	0.07
	100	Deming slope	1.09 (1.05 to 1.13)	0.97
		Deming intercept	0.12 (-0.01 to 0.25)	

Deming Regression Analysis: Slope was 1.09, and intercept

was 0.12 with a correlation coefficient of 0.97.



MYCOPHENOLIC ACID (MPA) ASSAY

Thermo Scientific CEDIA Mycophenolic Acid (MPA) Assay

Accurate: Correlates well with gold standard method LC-MS/MS Efficient: Two-point linear calibration

Rapid: No extraction step

Limit Of Quantitation (LOQ): 0.3 µg/mL

Reportable Range: 0.3 to 10 $\mu\text{g/mL}$

Precision

Control samples were tested in replicates of 2, twice per day for 20 days, yeilding a total of 80 replicates.

Sample	Mean (µg/mL)	Within-Run		Total	
		SD (µg/mL)	%CV	SD (µg/mL)	%CV
Control 1	0.88	0.05	5.10	0.07	8.10
Control 2	2.84	0.06	1.90	0.08	2.90
Control 3	6.55	0.11	1.70	0.19	2.90

Ordering:

Item Number	Description	Format
10016265	CEDIA Mycophenolic Acid Assay	R1 26 mL, R2 11 mL
100277	CEDIA Mycophenolic Acid Calibrator Set	2 levels, 5.0 mL 2 vials each
100278	MAS [™] Mycophenolic Acid Control 1 Kit	1 level, 5.0 mL 4 vials each
100279	MAS Mycophenolic Acid Control 2 Kit	1 level, 5.0 mL 4 vials each
100280	MAS Mycophenolic Acid Control 3 Kit	1 level, 5.0 mL 4 vials each

Introgeness Corpotation





We offer a comprehensive menu of Immunosuppressant Drug Management assays, which are recognized worldwide for their ease-of-use, quality, performance, and lot-to-lot consistency.

- Full ISD menu on a single analyzer
- Convenient on-site testing
- Improved laboratory efficiency and turnaround time

Description	Sample Type	
CEDIA Cyclosporine PLUS Assay	Whole blood	
QMS Tacrolimus Immunoassay	Whole blood	
CEDIA Mycophenolic Acid Assay	Plasma	
QMS Everolimus Immunoassay	Whole blood	

IMMUNOSUPPRESSANT DRUG TESTING

thermoscientific

Clinical Diagnostics

USA

46500 Kato Road Fremont, CA 94538 USA Tel. 800-232-3342 / + 1 510-979-5000 sales.diagnostics.fmt@thermofisher.com

Asia Pacific Tel. +65 6499 9999 cdd.asia.info2@thermofisher.com

Australia Tel. + 61 1800 333 110 auinfo@thermofisher.com

Canada Tel. 905-286-4290 CDD.Canada@thermofisher.com

China

Tel. +86 400 650 5118 sales.china@thermofisher.com

France, Belgium (Brussels / Wallonia) & Luxembourg Tel. + 33 (0) 1 40 86 65 00 cdx.fr.info@thermofisher.com

Germany Tel. +49 (0) 3302 883 608 cdx.de.info@thermofisher.com

Hong Kong Tel. + 852 3107 7600 sales.hk@thermofisher.com

Italy distributor.cdd@thermofisher.com

Japan

Tel. + 81 (0)120-147-075 JPYOK-CDD.QC@thermofisher.com

Netherlands & Belgium (Flemish) Tel. +49 3302 883 660 Info.benelux.cdd@thermofisher.com

New Zealand Tel. + 61 0800933 966 nzinfo@thermofisher.co.nz

Nordic Tel. + 46 8 594 691 30 info.nordic.cdd@thermofisher.com Russia

Tel. + 7 495 739 76 41 info.btd.moscow@thermofisher.com South Africa Tel. +27 11 792 6790 support-za.idd@thermofisher.com

Spain & Portugal (Iberia) Tel. + 34 93589 8338 CDD.Info.ES@thermofisher.com

Switzerland & Austria Tel. + 41 26 663 86 70 cdx.ch.info@thermofisher.com

United Kingdom & Ireland Tel. + 44 1442 868 940

cdx.UK.info@thermofisher.com For Countries Not Listed

distributor.cdd@thermofisher.com

Find out more at thermofisher.com/diagnostics

© 2018 Thermo Fisher Scientific Inc. All rights reserved. Copyrights in and to portions of the illustrations are owned by a third party and licensed for limited use only to Thermo Fisher Scientific by Getty Images. CEDIA is a registered trademark of Roche Diagnostics. Beckman Coulter is a registered trademarks of Beckman Coulter, Inc. "Abbott" and "Architect" are trademarks of Abbott laboratories. "Hitachi" is a trademark of Hitachi Ltd. Windows is a registered trademark of Microsoft Corporation. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. Information and technical specifications are subject to change without notice. **BR10017513-3MTL-ISD-EN 2018 07**

Thermo Fisher S C I E N T I F I C